시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 세포 용해 및 분획 시장 보고서(2025년)
Cell Lysis And Fractionation Global Market Report 2025
상품코드 : 1824607
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,493,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,386,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,279,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세포 용해 및 분획 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 7.0%를 나타내 48억 3,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 맞춤형 의료에 대한 주목 증가, 연구에 대한 정부 자금 증가, 효과적인 수법에 대한 높은 수요, 유전체학와 단백질체학의 분야에서의 기술 진보, 만성 질환과 감염증의 유병률의 상승 등에 기인하고 있습니다. 예측 기간의 주요 동향으로는 맞춤형 의료 접근의 채용의 지속적인 성장, 용해·분획 프로세스에 있어서의 자동화·로봇화의 진전, 임상 진단 및 의약품 개발에 있어서의 용도의 확대, 세포 분석용 마이크로플루이딕스 및 라보온칩 기술의 진보, POC(Point-of-Care) 및 분산형 검사 솔루션의 중시의 고조등을 들 수 있습니다.

향후 5년간의 성장률 7.0%라고 하는 예측은 전회의 예측으로부터 0.1%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 부과는 영국과 덴마크에서 수입되는 고압 균질화기 및 아세포 분획 키트에 대한 액세스를 제한하고 바이오마커 탐색을 12-18개월 지연시킬 수 있으므로 미국 단백질체학에 심각한 과제를 초래할 수 있습니다. 또한, 상호관세와 무역마찰의 격화와 제한에 의한 세계경제와 무역에 대한 악영향에 의해 그 영향은 보다 광범위하게 미칠 것으로 보입니다.

맞춤형 의료에 대한 관심 증가는 미래의 세포 용해 및 분획 시장 성장을 가속할 것으로 예측됩니다. 맞춤형 의료는 개인의 유전자 프로파일을 질병의 진단과 치료에 이용하는 새로운 의료 행위입니다. 이 의학은 의료 결정과 치료를 각 환자의 특성, 특히 유전자 구성에 초점을 맞추고 조정합니다. 세포용해 및 분획은 단백질, 세포소기관, 핵산 등 환자의 샘플에서 특정 세포내 요소를 분리·분석할 수 있게 함으로써 정밀의료에서 중요한 역할을 하고 있습니다. 이를 통해 과학자와 의료 전문가는 질병의 근본적인 분자 과정을 조사하고 각 환자의 독특한 분자 특성에 따라 맞춤형 치료를 만들 수 있습니다. 예를 들어, 맞춤형 의료의 이해와 보급을 추진하는 미국의 단체, 맞춤형 의료 연합(PMC)에 따르면, 2022년 10월에는 복수 유형의 암, 유전성 희귀질환, 다양한 만성 질환이나 감염증의 환자를 대상으로, 7만 5,000 이상의 유전자 검사 제품과 300 이상의 개별화 의약품이 시장에 출회했습니다. 따라서 맞춤형 의료에 대한 관심 증가는 세포 용해 및 분획 시장 성장을 이끌고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Cell lysis is the process of breaking open a cell, which allows the release of its contents, while cell fractionation is a multi-step laboratory procedure used to divide a cell's organelles into various layers or fractions or sections.

The main types of cell lysis and fractionation are mammalian cells and microbial cells. Mammalian cells are eukaryotic cells that are derived from mammals and are used in cell culture and biomanufacturing of therapeutic proteins and viral vaccines. These are used for various applications, such as nucleic acid purification and isolation and protein purification and isolation, and are used by several end users, including research laboratories and institutes, biopharmaceutical, and biotechnology companies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The main types of cell lysis and fractionation are mammalian cells and microbial cells. Mammalian cells are eukaryotic cells that are derived from mammals and are used in cell culture and biomanufacturing of therapeutic proteins and viral vaccines. These are used for various applications, such as nucleic acid purification and isolation and protein purification and isolation, and are used by several end users, including research laboratories and institutes, biopharmaceutical, and biotechnology companies.

The cell lysis and fractionation market size has grown strongly in recent years. It will grow from $3.42 billion in 2024 to $3.69 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increasing investments in life science research, growing focus on personalized medicine, high prevalence of diseases, technological advancements in cell lysis and fractionation methods, rising demand for biopharmaceuticals and biotechnology products.

The cell lysis and fractionation market size is expected to see strong growth in the next few years. It will grow to $4.83 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to growing focus on personalized medicine, increasing government funding for research, high demand for effective cell lysis and fractionation methods, technological advancements in the field of genomics and proteomics, rising prevalence of chronic and infectious diseases. Major trends in the forecast period include continued growth in the adoption of personalized medicine approaches, increasing integration of automation and robotics in lysis and fractionation processes, expansion of applications in clinical diagnostics and drug development, advancements in microfluidics and lab-on-a-chip technologies for cell analysis, growing emphasis on point-of-care and decentralized testing solutions.

The forecast of 7.0% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose significant challenges for U.S. proteomics by restricting access to high-pressure homogenizers and subcellular fractionation kits imported from the UK and Denmark, potentially delaying biomarker discovery by 12-18 months. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

A growing focus on personalized medicine is expected to propel the growth of the cell lysis and fractionation markets going forward. Personalized medicine is an emerging practice of medicine that uses an individual's genetic profile for the diagnosis and treatment of disease. It involves tailoring medical decisions and treatments to the individual characteristics of each patient, particularly focusing on their genetic makeup. Cell lysis and fractionation play a crucial part in precision medicine by making it possible to separate and analyze particular subcellular elements from patient samples, including proteins, organelles, and nucleic acids. This makes it possible for scientists and medical professionals to investigate the molecular processes that underlie illness and create customized treatments depending on the unique molecular traits of each patient. For instance, in October 2022, according to the Personalized Medicine Coalition (PMC), a US-based organization that promotes understanding and adoption of personalized medicine, more than 75,000 genetic testing products and 300 personalized medicines will be on the market for people with multiple types of cancer, genetic rare diseases, and a range of chronic and infectious diseases. Therefore, the growing focus on personalized medicine is driving the growth of the cell lysis and fractionation markets.

Major companies operating in the cell lysis and fractionation market are focused on introducing advanced solutions, such as CGT (cell and gene therapy) viral vector lysis kits, to gain a competitive edge in the market. These lysis kits offer a simplified AAV (Adeno-associated virus) lysis methodology that will improve SOPs (Standard Operating Procedures), quality control, and safety while standardizing bioprocessing workflows. For instance, in July 2023, QIAGEN, a Germany-based provider of sample and assay technologies, launched the new CGT Viral Vector Lysis Kit, which makes it possible to quantify virus titers for several serotypes with an exact and uniform procedure starting with cell lysates. The new CGT viral vector lysis kit complements QIAGEN's rapidly expanding digital PCR portfolio for the biopharma industry, which already includes three QIAcuity Residual DNA Quantification Kits to check for host cell DNA carryover and ten QIAcuity Cell and Gene Therapy (CGT) dPCR Assays for use in adeno-associated virus (AAV) titer quantification.

In December 2022, MilliporeSigma, a US-based pharmaceutical company, acquired Erbi Biosystems Inc. for an undisclosed amount. With this acquisition, MilliporeSigma aims to strengthen its portfolio and expertise in the field of bioreactors and cell culture technologies. Erbi Biosystems is the developer of the 2 ml micro-bioreactor platform technology known as Breez, which is a micro-scale, fully automated, functionally closed system. Erbi Biosystems Inc. is a US-based biotechnology company that offers microfluidic solutions to enable efficient and controlled cell lysis and fractionation.

Major companies operating in the cell lysis and fractionation market are Hoffmann-La Roche Ltd, Merck & Co. Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, Lonza Group AG, Illumina Inc., Beckman Coulter Inc., PerkinElmer Inc., IDEX Corporation, Bio-Rad Laboratories Inc., QIAGEN NV, Eppendorf AG, Miltenyi Biotec B.V. & Co. KG, Promega Corporation, Takara Bio Inc., Abcam plc, Cell Signaling Technology Inc., BioVision Inc., Diagenode LLC, Claremont BioSolutions LLC, Norgen Biotek Corp., Qsonica LLC, Labfreez Instruments Group Co. Ltd.

North America was the largest region in the cell lysis and fractionation market in 2024. The regions covered in the cell lysis and fractionation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cell lysis and fractionation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cell lysis and fractionation market consists of revenues earned by entities by providing cellular contents extraction, cytoplasmic separation, and cell disruption. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell lysis and fractionation market also includes sales of cell lysis instruments, cell lysis reagents, and consumables. Values in this market are 'factory gate' values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cell Lysis And Fractionation Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cell lysis and fractionation market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for cell lysis and fractionation ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cell lysis and fractionation market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Cell Lysis And Fractionation Market Characteristics

3. Cell Lysis And Fractionation Market Trends And Strategies

4. Cell Lysis And Fractionation Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Cell Lysis And Fractionation Growth Analysis And Strategic Analysis Framework

6. Cell Lysis And Fractionation Market Segmentation

7. Cell Lysis And Fractionation Market Regional And Country Analysis

8. Asia-Pacific Cell Lysis And Fractionation Market

9. China Cell Lysis And Fractionation Market

10. India Cell Lysis And Fractionation Market

11. Japan Cell Lysis And Fractionation Market

12. Australia Cell Lysis And Fractionation Market

13. Indonesia Cell Lysis And Fractionation Market

14. South Korea Cell Lysis And Fractionation Market

15. Western Europe Cell Lysis And Fractionation Market

16. UK Cell Lysis And Fractionation Market

17. Germany Cell Lysis And Fractionation Market

18. France Cell Lysis And Fractionation Market

19. Italy Cell Lysis And Fractionation Market

20. Spain Cell Lysis And Fractionation Market

21. Eastern Europe Cell Lysis And Fractionation Market

22. Russia Cell Lysis And Fractionation Market

23. North America Cell Lysis And Fractionation Market

24. USA Cell Lysis And Fractionation Market

25. Canada Cell Lysis And Fractionation Market

26. South America Cell Lysis And Fractionation Market

27. Brazil Cell Lysis And Fractionation Market

28. Middle East Cell Lysis And Fractionation Market

29. Africa Cell Lysis And Fractionation Market

30. Cell Lysis And Fractionation Market Competitive Landscape And Company Profiles

31. Cell Lysis And Fractionation Market Other Major And Innovative Companies

32. Global Cell Lysis And Fractionation Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cell Lysis And Fractionation Market

34. Recent Developments In The Cell Lysis And Fractionation Market

35. Cell Lysis And Fractionation Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기